Association Studies of MMP-9 in Parkinson's Disease and Amyotrophic Lateral Sclerosis

PLoS ONE

Volumn 8, Issue 9, 2013, Pages

  He, Xianghua ^a   Zhang, Lifang ^b   Yao, Xiaoli ^c   Hu, Jing ^d   Yu, Lihua ^a   Jia, Hua ^a   An, Ran ^a   Liu, Zhuolin ^c   Xu, Yanming ^a  

^a SICHUAN UNIVERSITY   (China)

^b NINGXIA MEDICAL UNIVERSITY   (China)

^c HEBEI MEDICAL UNIVERSITY   (China)

^d SUN YAT SEN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

GELATINASE B;

ADULT; AGED; AMYOTROPHIC LATERAL SCLEROSIS; ARTICLE; CHINA; CONTROLLED STUDY; FEMALE; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC PREDISPOSITION; GENETIC RISK; HUMAN; MAJOR CLINICAL STUDY; MALE; MMP 9 GENE; MOLECULAR PATHOLOGY; PARKINSON DISEASE; RESTRICTION FRAGMENT LENGTH POLYMORPHISM;

ADULT; AGED; ALLELES; AMYOTROPHIC LATERAL SCLEROSIS; ASIAN CONTINENTAL ANCESTRY GROUP; CHINA; FEMALE; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; MALE; MATRIX METALLOPROTEINASE 9; MIDDLE AGED; ODDS RATIO; PARKINSON DISEASE; POLYMERASE CHAIN REACTION; POLYMORPHISM, GENETIC; POLYMORPHISM, RESTRICTION FRAGMENT LENGTH; RISK FACTORS;

EID: 84883645853     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0073777     Document Type: Article

References (39)

1. Oshiro S, Morioka MS, Kikuchi M, (2011) Dysregulation of iron metabolism in Alzheimer's disease, Parkinson's disease, and amyotrophic lateral sclerosis. Adv Pharmacol Sci 2011: 378278.
2. Matés JM, Segura JA, Alonso FJ, Márquez J, (2010) Roles of dioxins and heavy metals in cancer and neurological diseases using ROS-mediated mechanisms. Free Radic Biol Med 49: 1328-1341.
3. Martin LJ, (2007) Transgenic mice with human mutant genes causing Parkinson's disease and amyotrophic lateral sclerosis provide common insight into mechanisms of motor neuron selective vulnerability to degeneration. Rev Neurosci 18: 115-136.
4. Uitti RJ, Berry K, Yasuhara O, Eisen A, Feldman H, et al. (1995) Neurodegenerative 'overlap' syndrome: Clinical and pathological features of Parkinson's disease, motor neuron disease, and Alzheimer's disease. Parkinsonism Relat Disord 1: 21-34.
5. Hedera P, Lerner AJ, Castellani R, Friedland RP, (1995) Concurrence of Alzheimer's disease, Parkinson's disease, diffuse Lewy body disease, and amyotrophic lateral sclerosis. J Neurol Sci 128: 219-224.
6. Hudson AJ, (1991) Amyotrophic lateral sclerosis/parkinsonism/dementia: clinico-pathological correlations relevant to Guamanian ALS/PD. Can J Neurol Sci 18: 387-389.
7. Farníková K, Kanovský P, Nestrasil I, Otruba P, (2010) Coexistence of parkinsonism, dementia and upper motor neuron syndrome in four Czech patients. J, Neurol Sci 296: 47-54.
8. Gilbert RM, Fahn S, Mitsumoto H, Rowland LP, (2010) Parkinsonism and motor neuron diseases: twenty-seven patients with diverse overlap syndromes. Mov Disord 25: 1868-1875.
9. Logroscino G, Traynor BJ, Hardiman O, Chio' A, Couratier P, et al. (2008) Descriptive epidemiology of amyotrophic lateral sclerosis: new evidence and unsolved issues. J, Neurol Neurosurg Psychiatry 79: 6-11.
10. Majoor-Krakauer D, Ottman R, Johnson WG, Rowland LP, (1994) Familial aggregation of amyotrophic lateral sclerosis, dementia, and Parkinson's disease: evidence of shared genetic susceptibility. Neurology 44: 1872-1877.
11. Quadri M, Cossu G, Saddi V, Simons EJ, Murgia D, et al. (2011) Broadening the phenotype of TARDBP mutations: the TARDBP Ala382Thr mutation and Parkinson's disease in Sardinia. Neurogenetics 12: 203-209.
12. van Es MA, Schelhaas HJ, van Vught PW, Ticozzi N, Andersen PM, et al. (2011) Angiogenin variants in Parkinson disease and amyotrophic lateral sclerosis. Ann Neurol 70: 964-973.
13. Lesnick TG, Sorenson EJ, Ahlskog JE, Henley JR, Shehadeh L, et al. (2008) Beyond Parkinson disease: amyotrophic lateral sclerosis and the axon guidance pathway. PLoS One 3: e1449.
14. Ross OA, Rutherford NJ, Baker M, Soto-Ortolaza AI, Carrasquillo MM, et al. (2011) Ataxin-2 repeat-length variation and neurodegeneration. Hum Mol Genet 20: 3207-3212.
15. Xi Z, Zinman L, Grinberg Y, Moreno D, Sato C, et al. (2012) Investigation of c9orf72 in 4 neurodegenerative disorders. Arch Neurol 69: 1583-1590.
16. O'Dowd S, Curtin D, Waite AJ, Roberts K, Pender N, et al. (2012) C9ORF72 expansion in amyotrophic lateral sclerosis/frontotemporal dementia also causesparkinsonism. Mov Disord 27: 1072-1074.
17. Majounie E, Abramzon Y, Renton AE, Keller MF, Traynor BJ, et al. (2012) Large C9orf72 repeat expansions are not a common cause of Parkinson's disease. Neurobiol Aging 33, 2527.e1-e2.
18. van Rheenen W, van Blitterswijk M, Huisman MH, Vlam L, van Doormaal PT, et al. (2012) Hexanucleotide repeat expansions in C9ORF72 in the spectrum of motor neuron diseases. Neurology 79: 878-882.
19. Lorenzl S, Calingasan N, Yang L, Albers DS, Shugama S, et al. (2004) Matrix metalloproteinase-9 is elevated in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced parkinsonism in mice. Neuromolecular Med 5: 119-132.
20. Lorenzl S, Albers DS, LeWitt PA, Chirichigno JW, Hilgenberg SL, et al. (2003) Tissue inhibitors of matrix metalloproteinases are elevated in cerebrospinal fluid of neurodegenerative diseases. J, Neurol Sci 207: 71-76.
21. Kim SY, Woo MS, Park JS, Kim HS, (2010) Regulation of matrix metalloproteinase-9 gene expression in MPP+- or 6-OHDA-treated human neuroblastoma SK-N-BE(2)C cells. Neurochem Int 56: 437-442.
22. Niebroj-Dobosz I, Janik P, Sokołowska B, Kwiecinski H, (2010) Matrix metalloproteinases and their tissue inhibitors in serum and cerebrospinal fluid of patients with amyotrophic lateral sclerosis. European journal of neurology: the official journal of the European Federation of Neurological Societies 17: 226-231.
23. Fang L, Huber-Abel F, Teuchert M, Hendrich C, Dorst J, et al. (2009) Linking neuron and skin: matrix metalloproteinases in amyotrophic lateral sclerosis (ALS). J Neurol Sci 285: 62-66.
24. Sokolowska B, Jozwik A, Niebroj-Dobosz I, Janik P, Kwiecinski H, (2009) Evaluation of matrix metalloproteinases in serum of patients with amyotrophic lateral sclerosiswith pattern recognition methods. J Physiol Pharmacol 60Suppl 5: 117-120.
25. Zhang B, Ye S, Herrmann SM, Eriksson P, de Maat M, et al. (1999) Functional polymorphism in the regulatory region of gelatinase B gene in relation to severity of coronary atherosclerosis. Circulation 99: 1788-1794.
26. Zawiślak D, Borratyńska A, Tomik B, Pera J, Gryz-Kurek E, et al. (2009) The C(-1562)T polymorphism of the MMP-9 gene and the risk of sporadic amyotrophic lateral sclerosis. Neurol Neurochir Pol 43: 121-125.
27. Iłżecka J, (2011) EMMPRIN levels in serum of patients with amyotrophic lateral sclerosis. Acta Neurol Scand 124: 424-428.
28. Hughes AJ, Daniel SE, Kilford L, Lees AJ, (1992) Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry 55: 181-184.
29. Farrer MJ, Hulihan MM, Kachergus JM, Dächsel JC, Stoessl AJ, et al. (2009) DCTN1 mutations in Perry syndrome. Nat Genet 41: 163-165.
30. Münch C, Rosenbohm A, Sperfeld AD, Uttner I, Reske S, et al. (2005) Heterozygous R1101K mutation of the DCTN1 gene in a family with ALS and FTD. Ann Neurol 58: 777-780.
31. Vincenti MP, Brinckerhoff CE, (2007) Signal transduction and cell-type specific regulation of matrix metalloproteinase gene expression: can MMPs be good for you? J Cell Physiol 213: 355-364.
32. Weydt P, Yuen EC, Ransom BR, Möller T, (2004) Increased cytotoxic potential of microglia from ALS-transgenic mice. Glia 48: 179-182.
33. Lim GP, Backstrom JR, Cullen MJ, Miller CA, Atkinson RD, et al. (1996) Matrix metalloproteinases in the neocortex and spinal cord of amyotrophic lateral sclerosis patients. J, Neurochem 67: 251-259.
34. Ranganathan AC, Nelson KK, Rodriguez AM, Kim KH, Tower GB, et al. (2001) Manganese superoxide dismutase signals matrix metalloproteinase expression via H2O2-dependent ERK1/2 activation. J Biol Chem 276: 14264-14270.
35. Kiaei M, Kipiani K, Calingasan NY, Wille E, Chen J, et al. (2007) Matrix metalloproteinase-9 regulates TNF-alpha and FasL expression in neuronal, glial cells and its absence extends life in a transgenic mouse model of amyotrophic lateral sclerosis. Exp Neurol 205: 74-81.
36. Lorenzl S, Narr S, Angele B, Krell HW, Gregorio J, et al. (2006) The matrix metalloproteinases inhibitor Ro 28-2653 [correction of Ro 26-2853] extends survival in transgenic ALS mice. Exp Neurol 200: 166-1671.
37. Cauwe B, Opdenakker G, (2010) Intracellular substrate cleavage: a novel dimension in the biochemistry, biology and pathology of matrix metalloproteinases. Crit Rev Biochem Mol Biol 45: 351-423.
38. Lee EJ, Woo MS, Moon PG, Baek MC, Choi IY, et al. (2010) Alpha-synuclein activates microglia by inducing the expressions of matrix metalloproteinases and the subsequent activation of protease-activated receptor-1. J, Immunol 185: 615-623.
39. Joo SH, Kwon KJ, Kim JW, Kim JW, Hasan MR, et al. (2010) Regulation of matrix metalloproteinase-9 and tissue plasminogen activator activity by alpha-synuclein in rat primary glial cells. Neurosci Lett 469: 352-356.